Bimekizumab Sustains Complete Skin Clearance and Quality of Life Improvements Through Three Years in Plaque Psoriasis: Insights from the BE RADIANT Trial
Posted inDermatology news

Bimekizumab Sustains Complete Skin Clearance and Quality of Life Improvements Through Three Years in Plaque Psoriasis: Insights from the BE RADIANT Trial

The BE RADIANT trial demonstrates that bimekizumab provides rapid, superior, and durable skin clearance (PASI 100) and symptom relief compared to secukinumab over three years, with a manageable safety profile and significant quality-of-life benefits for patients with moderate-to-severe plaque psoriasis.
Dual-Action IgY and Cerium Oxide Nanofibrous Dressings Accelerate Scarless Healing in Infected Wound Models
Posted inDermatology Infectious Diseases news

Dual-Action IgY and Cerium Oxide Nanofibrous Dressings Accelerate Scarless Healing in Infected Wound Models

Researchers have developed a novel P/G@IYCe dressing combining yolk immunoglobulins and cerium oxide nanoparticles. This synergy effectively neutralizes bacterial pathogens and reactive oxygen species, facilitating rapid, high-quality skin regeneration and significantly reducing scar formation in infected full-thickness wound models.
Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD
Posted inDermatology news Oncology Transplantation

Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD

A multicenter study reveals significant discordance between clinician and patient assessments of skin cGVHD. While both correlate with survival, patient-reported outcomes are uniquely predictive of mortality in sclerotic disease, highlighting the need for integrated assessment models in clinical practice.
Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD
Posted inDermatology Gastroenterology news

Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD

An international multicenter study reveals that acne is a frequent adverse event in IBD patients treated with JAK inhibitors, particularly upadacitinib. The research highlights dose-dependency, significant psychosocial impacts, and the critical need for proactive dermatological management in clinical practice.
Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?
Posted inDermatology news Rheumatology

Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?

The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, highlighting potential steroid-sparing benefits in early intervention.